New vaccine aims to stop deadly diarrhea in kids
NCT ID NCT07666750
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new vaccine (IP-QSV) designed to protect against four types of Shigella bacteria, which cause severe diarrhea. The trial will include 370 healthy adults, children, and infants in Mali. Researchers will check if the vaccine is safe and triggers a strong immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Quadrivalent Shigella vaccine (IP-QSV) – a shot that targets four types of Shigella bacteria
What this could lead to
If successful, this could lead to a vaccine that protects against Shigella infection, a major cause of severe diarrhea in children.
What could go wrong
This is an early (Phase 1/2a) study, so the vaccine may not prove safe or effective. Results are limited to a specific region and may not apply elsewhere.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHIGELLA INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••